ClinicaliQ Trial Snapshot
- Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing — Active Not Recruiting • Phase III • Oncology • NCT05059522.
- Ongoing access to avelumab treatment for patients benefiting from it in completed Pfizer trials, with safety monitoring.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies. Conditions: Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors Interventions: Avelumab, Lorlatanib, Talazoparib, Pemetrexed, Axitinib, CMP 001, Utomilumab, PF04518600 Lead Sponsor: Pfizer Planned Enrollment: 77 participants